AM Cortisol: What Your Number Changes About Your Treatment

What AM Cortisol Actually Measures

An AM cortisol test captures serum total cortisol at the physiologic daily peak, driven by pulsatile ACTH secretion from the pituitary. Because cortisol follows a circadian rhythm that bottoms out around midnight and peaks between 6 and 9 a.m., a morning draw gives clinicians the highest-sensitivity window for detecting adrenal insufficiency (AI). Drawing the sample later in the day introduces significant variability and reduces diagnostic accuracy.

The Cortisol Awakening Response

Within 30 to 45 minutes of waking, healthy adults experience a cortisol surge of roughly 50 to 160% above baseline. This surge, sometimes called the cortisol awakening response (CAR), is a distinct neurobiological event separate from the broader circadian rise. A blunted or absent CAR can suggest hypothalamic-pituitary-adrenal (HPA) axis dysfunction even when a midday cortisol appears borderline normal. The CAR is not routinely measured in clinical labs, but understanding it explains why the 7 to 9 a.m. Draw window is non-negotiable for meaningful results.

Total vs. Free Cortisol

Standard serum assays measure total cortisol, which includes protein-bound fractions (roughly 90% is bound to cortisol-binding globulin and albumin). Elevated cortisol-binding globulin, such as the increase seen with oral estrogen therapy, can raise total cortisol readings by 2 to 3 mcg/dL without reflecting true bioavailable cortisol. The Endocrine Society's 2016 clinical practice guideline on adrenal insufficiency explicitly notes this confound and recommends that clinicians account for CBG-altering medications before interpreting results [1].

Normal AM Cortisol Range and How to Read Your Report

The normal reference range printed on most lab reports spans approximately 6 to 23 mcg/dL (165 to 635 nmol/L in SI units), though specific lab-to-lab variation exists. The Endocrine Society's diagnostic threshold framework uses three actionable tiers, not a binary normal/abnormal split.

The Three Diagnostic Tiers

Tier 1: AM cortisol < 3 mcg/dL (82 nmol/L). This result is diagnostic of adrenal insufficiency in a patient who was not taking exogenous glucocorticoids at the time of the draw. No further stimulation testing is required to establish the diagnosis, though confirming primary versus secondary AI still requires plasma ACTH measurement.

Tier 2: AM cortisol 3 to 18 mcg/dL (82 to 497 nmol/L). This is the indeterminate zone. The 2016 Endocrine Society guideline states: "We suggest performing a standard high-dose (250 mcg) ACTH stimulation test if the 8 a.m. Serum cortisol is less than 18 mcg/dL in a patient with signs or symptoms of AI" [1]. A peak cortisol <18 mcg/dL at 30 or 60 minutes post-stimulation confirms the diagnosis.

Tier 3: AM cortisol > 18 mcg/dL (497 nmol/L). An intact response at this level makes adrenal insufficiency very unlikely. Most clinicians use 18 mcg/dL as the functional rule-out threshold when drawn under correct conditions.

Why Lab Reference Ranges Differ

Immunoassay platforms vary. Electrochemiluminescence immunoassays (ECLIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) can produce results that differ by 10 to 20% on the same sample. LC-MS/MS is considered the gold standard. If your result is close to a decision threshold, confirming the assay method used and comparing to platform-specific ranges matters clinically.

What a Low AM Cortisol Means for Your Treatment

A low result below 3 mcg/dL, or a confirmatory stimulation test showing a blunted peak, changes the entire therapeutic plan. The treatment decisions that follow depend on whether the deficiency is primary (the adrenal glands themselves are failing) or secondary/tertiary (pituitary ACTH or hypothalamic CRH is insufficient).

Primary Adrenal Insufficiency (Addison Disease)

Primary AI requires lifelong glucocorticoid replacement and, in most cases, mineralocorticoid replacement as well. The standard glucocorticoid regimen is hydrocortisone 15 to 25 mg daily in two to three divided doses, with the largest dose given in the morning to mimic the circadian peak [2]. Fludrocortisone 0.05 to 0.2 mg once daily replaces aldosterone function. The AACE/ACE 2017 guidelines specify: "Hydrocortisone is the preferred glucocorticoid for replacement in primary adrenal insufficiency due to its short half-life and ease of dose adjustment" [3].

Patients on primary AI replacement should carry a 100 mg hydrocortisone injectable emergency kit and wear medical alert identification. Sick-day dosing rules (doubling or tripling the oral dose for fever, vomiting, or surgical stress) are non-negotiable components of the care plan.

Secondary Adrenal Insufficiency

Secondary AI, which can result from long-term glucocorticoid use, pituitary adenoma, or hypopituitarism, typically does not require mineralocorticoid replacement because the renin-angiotensin-aldosterone axis remains intact. Hydrocortisone 15 to 20 mg daily, or the equivalent in prednisone 3 to 5 mg/day or dexamethasone 0.25 to 0.5 mg/day, is the standard approach [1]. Patients transitioning from pharmacologic glucocorticoids (for example, prednisone >5 mg/day for more than three weeks) may need a gradual taper protocol over months, with periodic AM cortisol checks to confirm HPA axis recovery.

Impact on Other Hormone Therapies

Low AM cortisol often coexists with other endocrine disruptions. When a patient on testosterone replacement therapy (TRT) or menopausal hormone therapy (HRT) presents with unexplained fatigue, weight loss, or hypotension, an AM cortisol should be drawn before assuming the fatigue is from suboptimal hormone dosing. Starting TRT or HRT in a patient with undiagnosed AI can precipitate an adrenal crisis by increasing metabolic demand without adequate cortisol reserve. Cortisol replacement must be established first.

What a High AM Cortisol Means for Your Treatment

An AM cortisol consistently above 23 to 25 mcg/dL, especially paired with clinical signs, redirects workup toward cortisol excess rather than deficiency. Cushing syndrome affects an estimated 10 to 15 per million people annually and is frequently missed for years before diagnosis [4].

Initial Screening vs. Diagnostic Confirmation

A single elevated AM cortisol is not diagnostic of Cushing syndrome. The Endocrine Society's 2008 Cushing syndrome guideline (reaffirmed 2022) recommends one of three initial screening tests: 24-hour urine free cortisol, late-night salivary cortisol (two measurements), or a 1 mg overnight dexamethasone suppression test [5]. An AM cortisol >1.8 mcg/dL after 1 mg dexamethasone at 11 p.m. The night prior constitutes a positive suppression test and triggers further workup.

Common Causes of Mildly Elevated AM Cortisol

Not every elevated AM cortisol indicates Cushing syndrome. Physiologic hypercortisolism, sometimes called pseudo-Cushing state, occurs with major depression, chronic alcohol use, morbid obesity (BMI >40), and uncontrolled type 2 diabetes. In a cohort study of 150 patients with major depressive disorder, 23% had AM cortisol values above 20 mcg/dL without meeting Cushing criteria [6]. Treating the underlying condition typically normalizes cortisol in these cases.

Treatment Options for Confirmed Cortisol Excess

If Cushing syndrome is confirmed, treatment depends on the source:

• Pituitary Cushing (Cushing disease): Transsphenoidal adenoma resection is first-line. Remission rates reach 65 to 90% in experienced centers. Pasireotide 0.3 to 0.9 mg SC twice daily is FDA-approved for patients who cannot have surgery or experience recurrence [7].
• Adrenal Cushing: Unilateral adrenalectomy for a cortisol-secreting adenoma achieves cure in the majority of cases.
• Ectopic ACTH syndrome: Treatment targets the primary tumor, but steroidogenesis inhibitors such as metyrapone 500 to 6,000 mg/day or ketoconazole 400 to 1,200 mg/day are used to control hypercortisolism while awaiting definitive treatment.
• Medical-only management: Osilodrostat (Isturisa), FDA-approved in 2020, inhibits 11-beta-hydroxylase and reduces cortisol production. In the LINC 3 trial (N=137), osilodrostat produced biochemical remission in 53% of patients at 36 weeks versus 29% placebo [7].

Medications and Substances That Interfere with AM Cortisol Results

Multiple drugs alter either cortisol production or its measured concentration. Failing to account for these before the draw can lead to misclassification and wrong treatment decisions.

Drugs That Suppress Cortisol

Inhaled corticosteroids, even at standard doses, can suppress the HPA axis. A 2019 meta-analysis of 74 studies (N=3,422) found that inhaled fluticasone propionate at doses >500 mcg/day was associated with biochemical adrenal suppression in approximately 20% of adults [8]. Systemic prednisone, dexamethasone, budesonide, methylprednisolone, and topical high-potency steroids applied over large skin areas all carry suppression risk. If a patient is currently using any of these, the AM cortisol reflects drug effect rather than baseline adrenal function.

The standard protocol at HealthRX is to hold exogenous glucocorticoids for at least 12 to 24 hours before the draw when clinically safe, or to document ongoing use and interpret the result accordingly.

Drugs That Raise Cortisol or CBG

Oral estrogen (including ethinyl estradiol in combined oral contraceptives and estradiol taken orally in HRT) raises cortisol-binding globulin and can inflate total cortisol by 2 to 5 mcg/dL. Transdermal or vaginal estradiol has a much smaller effect on CBG and produces less interference. Carbamazepine and mitotane induce CYP3A4 and accelerate cortisol clearance, which can falsely lower results. Etomidate, even a single anesthetic dose, blocks cortisol synthesis for 6 to 8 hours.

The AM Cortisol Draw Protocol That Prevents Errors

Getting an accurate result requires following a specific collection protocol. Errors in timing or preparation account for a large proportion of borderline-ambiguous results that trigger unnecessary additional testing.

Timing and Preparation

• Draw blood between 7:00 and 9:00 a.m. Draws after 9:30 a.m. May show a 2 to 4 mcg/dL decline from peak as the circadian rhythm descends.
• The patient should have been awake for at least 30 minutes before the draw to capture the post-awakening cortisol peak, not the sleep nadir.
• Fasting is not strictly required but is preferred to avoid lipemia artifacts.
• Hold any oral glucocorticoid until after the blood draw on that morning.
• Document the exact draw time on the lab requisition.

Stress Confounds

Acute physical or psychological stress can raise cortisol by 5 to 10 mcg/dL within 15 to 30 minutes. A painful venipuncture, a tense waiting room, or a drive through traffic can all shift the result. If a patient is acutely ill, in pain, or coming off an overnight hospital stay, the result may reflect stress hypercortisolemia rather than baseline adrenal function. Repeating the test under calmer conditions, or using a different diagnostic modality (salivary cortisol collected at home), produces more reliable baseline data.

AM Cortisol in Specific HealthRX Treatment Populations

Certain patient groups seen frequently at HealthRX have unique considerations when interpreting an AM cortisol result.

Patients on GLP-1 Receptor Agonists

Semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) cause rapid weight loss that can unmask previously compensated secondary adrenal insufficiency, particularly in patients with prior long-term steroid use or known pituitary disease. A baseline AM cortisol before starting a GLP-1 agonist is reasonable in any patient with a history of chronic glucocorticoid use or unexplained fatigue.

Patients on Testosterone Replacement Therapy

Testosterone modestly affects cortisol metabolism. Men with hypogonadism treated with testosterone cypionate or enanthate may experience small changes in cortisol-binding protein levels, though the clinical magnitude is generally minor. The more relevant overlap is that symptoms of adrenal insufficiency (fatigue, low libido, weight loss, salt craving) can mimic hypogonadism symptoms. An AM cortisol drawn before initiating TRT prevents missing a concurrent AI diagnosis.

Patients on Menopausal HRT

As noted in the section on CBG interference, oral estradiol raises total cortisol measurements. A woman starting oral HRT who had a prior borderline low AM cortisol of 8 mcg/dL may, after six weeks of oral estradiol, show a result of 11 to 13 mcg/dL without any actual improvement in adrenal function. Switching to transdermal estradiol 0.05 to 0.1 mg/day patch or gel before repeating the AM cortisol gives a cleaner result for diagnostic purposes.

How Often AM Cortisol Should Be Monitored on Replacement

Once a patient is on glucocorticoid replacement therapy for adrenal insufficiency, the AM cortisol is no longer the primary monitoring tool. Dosing is guided by clinical response, not by target serum levels, because exogenous hydrocortisone itself shows up in the cortisol assay.

Monitoring on replacement should include:

• Annual clinical review of symptoms (fatigue, weight, blood pressure, electrolytes)
• Sodium and potassium to assess mineralocorticoid adequacy in primary AI
• Bone density (DXA scan every 2 years) because even physiologic glucocorticoid replacement carries long-term bone resorption risk
• DHEA-S levels annually in women with primary AI, as adrenal androgen loss is near-complete and DHEA 25 to 50 mg/day supplementation may improve quality of life per the Endocrine Society guideline [1]

Patients suspected of over-replacement (weight gain, glucose intolerance, easy bruising) should have their dose reduced rather than confirmed by AM cortisol, since the assay cannot distinguish endogenous from exogenous cortisol reliably at replacement doses.

How to Raise a Low AM Cortisol (When It Is Clinically Appropriate)

"How to raise AM cortisol" is a common search query, but the correct answer depends on whether the low value is pathologic or situational. A truly low cortisol from adrenal insufficiency requires pharmaceutical replacement, not lifestyle modification. Lifestyle interventions matter only for suboptimal cortisol output within a functioning HPA axis, such as chronic stress-driven HPA blunting, which is distinct from actual AI.

Lifestyle Factors That Support HPA Axis Function

Chronic sleep deprivation significantly disrupts the cortisol awakening response. A randomized crossover study (N=23) found that five consecutive nights of sleep restricted to 4 hours per night reduced CAR amplitude by roughly 19% compared to 8-hour sleep nights [9]. Consistent sleep timing, targeting 7 to 9 hours, is the single most evidence-supported behavioral intervention for normalizing morning cortisol rhythm.

Moderate aerobic exercise (30 to 45 minutes at 60 to 70% VO2max, three to five days per week) supports healthy HPA reactivity without driving chronic hypercortisolism. Very high training volumes in competitive athletes can suppress morning cortisol and blunt CAR, a phenomenon well-documented in overtraining syndrome.

Chronic caloric restriction below approximately 1,200 kcal/day in women and 1,500 kcal/day in men, such as during aggressive GLP-1-assisted weight loss, can modestly lower morning cortisol. This rarely causes clinical AI but may explain fatigue complaints during rapid weight loss phases.

How to Lower a High AM Cortisol (When It Is Clinically Appropriate)

Physiologic hypercortisolemia from chronic psychosocial stress responds, at least partially, to behavioral interventions. A 2021 systematic review of 24 randomized trials found that mindfulness-based stress reduction (MBSR) programs of 8 weeks reduced morning cortisol by a mean of 1.4 mcg/dL (38 nmol/L) compared to waitlist controls [10]. The effect size is modest and clinically meaningful only for borderline-elevated results; it does not treat Cushing syndrome.

Ashwagandha (Withania somnifera) extract at 300 to 600 mg/day for 8 weeks reduced serum cortisol by approximately 14 to 28% versus placebo in a double-blind RCT (N=64) [11]. The Endocrine Society does not endorse adaptogen supplements as treatment for any defined adrenal disorder, and these supplements are not a substitute for medical evaluation when cortisol is genuinely elevated.

For confirmed Cushing syndrome, pharmacologic lowering of cortisol uses the agents described above (osilodrostat, metyrapone, ketoconazole, or pasireotide), and decisions should be made by an endocrinologist, not self-managed.